|
Status |
Public on Dec 22, 2010 |
Title |
AML_34neg_TLA_SU028 |
Sample type |
RNA |
|
|
Source name |
therapeutic leukapheresis
|
Organism |
Homo sapiens |
Characteristics |
patient: SU028 age group: adult disease state: AML cell source: therapeutic leukapheresis cell type (purified cell subset): Lin-CD34-
|
Extracted molecule |
total RNA |
Extraction protocol |
Total RNA was extracted using TRIzol reagent containing either glycogen or linear acrylamide according to the manufacturer's protocol, and then treated with DNaseI (Ambion).
|
Label |
biotin
|
Label protocol |
Standard Affymetrix IVT labeling protocol. See Affymetrix Expression Analysis Technical Manual
|
|
|
Hybridization protocol |
Following fragmentation, ten micrograms of adjusted cRNA fromeach sample was hybridized for 16 hours at 45 deg C to Affymetrix GeneChip
|
Scan protocol |
Scanning was performed using the Affymetrix GeneChip 3000 Scanner. Images were processed into CEL files with the Affymetrix GCOS software.
|
Description |
Majeti_28_34neg.CEL
|
Data processing |
Raw CEL intensity data were normalized using MAS5
|
|
|
Submission date |
Sep 07, 2010 |
Last update date |
Dec 22, 2010 |
Contact name |
Ash A Alizadeh |
E-mail(s) |
arasha@stanford.edu
|
Organization name |
Stanford University School of Medicine
|
Department |
Medicine, Divisions of Hematology and of Oncology
|
Lab |
Alizadeh
|
Street address |
269 Campus Drive, CCSR 1145c
|
City |
Stanford |
State/province |
CA |
ZIP/Postal code |
94305 |
Country |
USA |
|
|
Platform ID |
GPL10881 |
Series (1) |
GSE24006 |
A Leukemic Stem Cell Expression Signature is Associated with Clinical Outcomes in Acute Myeloid Leukemia |
|